Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pozelimab,Cemdisiran,Ravulizumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Poze-Cemdi Combo Controls Intravascular Hemolysis in PNH Patients Vs Ravulizumab
Details : Veopoz (pozelimab) is a complement C5 inhibitor antibody, which is being evaluated in combination with cemdisiran for the treatment of paroxysmal nocturnal hemoglobinuria.
Product Name : Veopoz
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 07, 2024
Lead Product(s) : Pozelimab,Cemdisiran,Ravulizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cemdisiran
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cemdisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemoglobinuria, Paroxysmal.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 23, 2021
Lead Product(s) : Cemdisiran
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable